Two drugs approved for chronic hepatitis C infection

Traynor, Kate
July 2011
American Journal of Health-System Pharmacy;7/1/2011, Vol. 68 Issue 13, p1176
Academic Journal
The article reports on the FDA's approval of two hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir, marketed as Victrelis by Merck and telaprevir, marketed as Incivek by Vertex Pharmaceuticals, for the treatment of adults with chronic HCV infection caused by genotype 1 viruses. Details related to the treatment regimens of boceprevir and telaprevir therapies, their recommended dosage and common adverse events and risks associated with them are discussed. INSET: New drugs and dosage forms.


Related Articles

  • HCV protease inhibitors bring new options for patients. Traynor, Kate // American Journal of Health-System Pharmacy;8/1/2011, Vol. 68 Issue 15, p1372 

    The article reports the approval of boceprevir, marketed as Victrelis by Merck, and telaprevir, marketed as Incivek by Vertex Pharmaceuticals, for the management of hepatitis C virus (HCV) infection. It mentions that both drugs are HCV NS3/4A protease inhibitors, and offers information on their...

  • Simeprevir: First Global Approval. Vaidya, Asha; Perry, Caroline M. // Drugs;Dec2013, Vol. 73 Issue 18, p2093 

    Simeprevir (Sovriad TM) is a new direct-acting antiviral drug and a second-generation small-molecule NS3/4A serine protease inhibitor developed by Janssen and Medivir for the oral treatment of adults with genotype 1 and/or genotype 4 chronic hepatitis C virus (HCV) infection (chronic hepatitis...

  • Hepatitis C treatment options improving.  // Mayo Clinic Health Letter;Jan2013, Vol. 31 Issue 1, p4 

    The article reports that treatment with newly approved drugs, telaprevir and boceprevir, protease inhibitors, may be more effective for older adults with hepatitis C virus, than treatment with the standard therapies.

  • Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection. Rheem, Justin; Sundaram, Vinay; Saab, Sammy // Gastroenterology & Hepatology;May2015, Vol. 11 Issue 5, p294 

    The emergence of direct-acting antiviral (DAA) agents has revolutionized the treatment schema for hepatitis C virus (HCV) infection. From cure rates to tolerability, DAA agents have shown outstanding profiles compared with the prior therapy of pegylated interferon with ribavirin. However, the...

  • New molecular entities/biologics.  // Formulary;Aug2006, Vol. 41 Issue 8, p362 

    The article provides information related to several drug approvals by the U.S. Food and Drug Administration. A monoclonal antibody called Ranibizumab was approved for the treatment of age-related macular degeneration. An approval was granted to Darunavir, a protease inhibitor used for the...

  • Vorapaxar: First Global Approval. Poole, Raewyn; Elkinson, Shelley // Drugs;Jul2014, Vol. 74 Issue 10, p1153 

    Vorapaxar [Zontivity (US)], an orally active protease-activated receptor-1 (PAR-1) receptor antagonist, has been developed by Merck & Co for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). Vorapaxar...

  • Two new approvals bring hope to patients with hepatitis C. TANZI, MARIA G. // Pharmacy Today;Oct2015, p46 

    The article discusses the approval of two drugs Daclatasvir and a combination of Ombitasvir, paritaprevir, and ritonavir by the Food and Drug Association (FDA) and notes that these drugs helps in treating hepatitis C.

  • FDA approves two hepatitis C treatments.  // Infectious Disease News;Dec2013, Vol. 26 Issue 12, p7 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the once-daily oral nucleotide analog sofosbuvir and simeprevir for the treatment of hepatitis C virus infection as of December 2013.

  • Two new hep C meds approved. Highleyman, Liz // Bay Area Reporter;6/16/2011, Vol. 41 Issue 24, p1 

    The article reports on the approval of the first two antiviral drugs for the treatment of chronic hepatitis C, such as boceprevir (Victrealis) from Merck & Co. Inc. and telaprevir (Incivek) from Vertex Pharmaceuticals Inc., by the U.S. Food and Drug Administration.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics